BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2026)

BioXcel Therapeutics' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $502000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 535.44% year-over-year to $502000.0 in Q1 2026; TTM through Mar 2026 was $1.8 million, a 258.85% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 253.75% from the prior year.
• Amortization of Deferred Charges rose to $502000.0 in Q1 2026 per BTAI's latest filing, from $469000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $502000.0 in Q1 2026 and bottomed at -$267000.0 in Q4 2022.
• The 5-year median for Amortization of Deferred Charges is $264500.0 (2023), against an average of $233250.0.
• Across the five-year window, Amortization of Deferred Charges tumbled 73.03% in 2024 and soared 535.44% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at -$267000.0 in 2022, then jumped by 214.98% to $307000.0 in 2023, then declined by 27.69% to $222000.0 in 2024, then soared by 111.26% to $469000.0 in 2025, then grew by 7.04% to $502000.0 in 2026.
• Per Business Quant, the three latest BTAI Amortization of Deferred Charges figures stand at $502000.0 (Q1 2026), $469000.0 (Q4 2025), and $441000.0 (Q3 2025).